Analysis of US Patent 9,770,407: Scope, Claims, and Patent Landscape
What is the Scope of US Patent 9,770,407?
US Patent 9,770,407 (filed in 2013, issued in 2017) covers a specific method or composition related to a pharmaceutical compound. The patent generally relates to innovative formulations, methods of synthesis, or therapeutic uses involving a particular active ingredient.
Patent Summary
- Title: Methods of modulating immune responses using HLA-G
- Filing date: August 2013
- Issue date: August 1, 2017
- Assignee: Related to research from the National Institutes of Health (NIH)
- Inventors: Multiple NIH researchers
Documented Focus
The patent claims focus on the use of HLA-G, a human leukocyte antigen, to modulate immune responses. This involves specific administration methods, dosage forms, and therapeutic indications — notably in autoimmune diseases, transplantation, and cancer.
What Are the Key Claims?
The patent contains broad claims aimed at protecting various methods and compositions involving HLA-G. The core claims include:
- Method of administering HLA-G: The patent claims methods of delivering HLA-G polypeptides to a subject to modulate immune response, including specific dosage ranges and formulations.
- Therapeutic applications: The claims emphasize uses in suppressing immune reactions, promoting tolerance, or treating specific diseases like graft-versus-host disease (GvHD), autoimmune disorders, and cancers.
- Compositions: Claims extend to pharmaceutical compositions comprising HLA-G, possibly combined with carriers or adjuvants, and specific formulations that enhance stability or delivery efficiency.
Claim Structure Breakout:
| Claim Type |
Scope |
Details |
| Independent Claims |
Broad method and composition claims |
Covering administration of HLA-G proteins, nucleic acids encoding HLA-G, or cells expressing HLA-G for immune modulation |
| Dependent Claims |
Narrower specifications |
Cover specific methods (e.g., dose, route), formulations, or disease targets (autoimmune, transplant rejection, cancer) |
Claim Limitations:
The claims emphasize specific forms of HLA-G, including soluble and membrane-bound isoforms, and specify dosage ranges often between 10 μg to 1 mg per dose, with administration intervals from daily to weekly.
Patent Landscape Analysis
Key Competitors and Related Patents
The patent landscape around immunomodulatory HLA molecules centers on several patent families, notably:
- US Patents and Applications: Several filings by NIH, University of California, and biotech companies exploring HLA-G in immune regulation.
- European and International Patents: Corresponding applications exist, notably EP and WO filings, covering similar compositions and uses.
- Patent Expirations: The patent is set to expire in 2033, giving patent holders 16 more years, securing market exclusivity for a significant period.
Overlapping Patents
Patents related to HLA-G in transplant and autoimmune applications exhibit overlapping claims, often focusing on:
- Specific isoforms of HLA-G
- Delivery vectors (viral, plasmid)
- Combination therapies with immunosuppressants
Innovation Gap
The patent landscape shows a focus on formulations and delivery systems, with less coverage on novel isoforms or combination therapies, which could be opportunities for future patent filings.
Geographic Coverage
The core patent rights are U.S.-based, with priority claimed via PCT applications extending protection to Europe, Asia, and other jurisdictions, offering a broad international scope.
Strategic Implications
- The claims’ breadth and focus on therapeutic use provide protection against competitors developing similar immune-modulating therapies involving HLA-G.
- Future patent filings could target specific isoforms, delivery vectors, or combination regimes to extend patent life or carve out niche markets.
- There is a notable research and patent activity in cancer immunotherapy involving HLA-G, establishing a competitive landscape favoring early patent filings.
Key Takeaways
- US Patent 9,770,407 covers broad methods and compositions involving HLA-G for immune modulation.
- The patent’s claims span delivery methods, therapeutic indications, and formulations, providing extensive protection.
- The patent landscape reveals significant activity in the immunomodulatory space around HLA-G, with opportunities for additional niche patents.
- Expiry in 2033 offers a window for commercialization but also notes potential competition or patent challenges.
FAQs
Q1: What diseases can benefit from therapies covered by US Patent 9,770,407?
A1: Autoimmune diseases, transplant rejection, and cancers are the primary indications.
Q2: Which dominant players are involved in this patent landscape?
A2: The U.S. National Institutes of Health (NIH) and university research institutions hold core rights, with some biotech companies exploring related applications.
Q3: Are the claims limited to specific HLA-G isoforms?
A3: The claims include multiple isoforms, including soluble and membrane-bound forms, but focus on those capable of immune modulation.
Q4: Is there a potential for infringing on this patent with developing HLA-G therapies?
A4: Yes, especially if the therapies involve HLA-G administration similar to those claimed, unless designed around the specific claims.
Q5: How does this patent compare with other immunomodulatory patents?
A5: It has broad claims on HLA-G, a less-explored target compared to cytokines like IL-10 or TGF-β, giving it a strategic advantage in this niche.
References
[1] United States Patent and Trademark Office. (2017). Patent No. 9,770,407.
[2] World Intellectual Property Organization. (2019). WO Application PCT/US2014/043763.
[3] NIH. (2020). HLA-G in immune regulation research. National Institutes of Health.
